CLINICAL_TRIALS
trial_result
· 2017-03-16
Clinical Trial Update: N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma [Phase 2]
Summary
Phase 2 trial of Ultratrace™ Iobenguane I 131 in relapsed/refractory high-risk neuroblastoma has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Molecular Insight Pharmaceuticals, Inc. | Conditions: Neuroblastoma | Phase 2 | Status: COMPLETED | Results posted: 2017-03-16